oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Our Topics
Recent Posts
Contact
oncgnostics GmbH
BioInstrumentezentrum Jena
Winzerlaer Str. 2
07745 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
oncgnostics in China: Pitch, Trade Fair, and Meeting with Partner
UncategorizedDr. Martina Schmitz and Dr. Alfred Hansel, our CSO and CEO, have just come back from a visit in China, with days full of exciting events, dates and a few hours for sightseeing. Shenzhen – Finals of the “Innovation & Entrepreneurship International Convention (IEIC)” Having reached a […]
Test for Uterine Cancer in Portugal: Biotech Firm oncgnostics Grants Exclusive Licence for Cancer Screening Test
Press Releases, UncategorizedLisbon/Jena, April 16th 2018 – Speculum S.A. is the exclusive licence partner of oncgnostics GmbH for the screening test GynTect® in Portugal. The test is designed to further specify abnormal results in screening examinations and to help determine the best treatment approach. In January, the biotech firm oncgnostics GmbH from Jena (Germany), concluded an […]
Reliable test for cervical cancer triage now available in Slovakia and the Czech Republic: Biotech company oncgnostics concludes an exclusive partnership with the MEDIREX group
Press Releases, UncategorizedJena, January 31th 2018 – oncgnostics GmbH partners with the MEDIREX Group. MEDIREX thus holds the exclusive rights for marketing the test for early and reliable detection of cervical cancer, GynTect®, for Slovakia and the Czech Republic. Following their successful crowd-funding via the platform Seedmatch, oncgnostics GmbH takes the next step for internationalization: the […]
GynTect soon available in China: – oncgnostics grants exclusive license for GynTect to the Chinese SINOPHARM subsidiary CJMT – approval for the Chinese market planned
Press Releases, UncategorizedJena, April 5th, 2017: The Chinese pharma company Changchun Jienuo Medical Technology (CJMT), a subsidiary of the Chinese state-owned SINOPHARM Group (www.sinopharm.com/en), has purchased an exclusive license from oncgnostics (www.oncgnostics.com) for marketing GynTect® in China, Hongkong and Macao. The contract comprising four milestones rules the approval of GynTect® at the Chinese Food and Drug Agency […]
oncgnostics presents extended version of its cervical cancer diagnostics test GynTect at MEDICA
Press ReleasesJena, November 9th, 2016 – The biotech company oncgnostics (www.oncgnostics.com) will present its new version of the triage test GynTect – a test for the fast and reliable detection of cervical cancer – at the world-leading trade fair Medica. Between 14th and 17th of November 2016 the epigenetics experts will explain the advantages of the […]
Early detection of cervical cancer: „GynTect 2.0“- wider range of application by using a greater variety of patient samples
Press ReleasesJena, September 20th, 2016 – GynTect, a molecular diagnostic test developed by the biotech company oncgnostics, allows fast and reliable diagnostics of cervical cancer and the corresponding precancerous stages. The test has been revised now, offering an extension of its application, as compared to the first version. This extended version of GynTect is now available […]
An investment into life: we start a crowdfunding campaign via the platform Seedmatch – with prominent support!
UncategorizedThose who have once been suspected to suffer from a severe disease know all-too-well, how long and grueling it can be to wait for further examinations that might bring clarity. These days, weeks and months are often very stressful for the person affected – and seemingly endless. In the course of cervical cancer screening, an […]
Oncgnostics GmbH cooperates with SAYRE Therapeutics in India
Press ReleasesBangalore/Jena, 28.04.2016 – The biotech firm oncgnostics GmbH will start distributing its molecular diagnostic test GynTect for use in cervical cancer diagnostics in an exclusive partnership with Sayre Therapeutics. GynTect is a molecular test, which allows timely clarification, if a patient with abnormal Pap test finding and/or a positive test for the cancer-causing human papillomaviruses […]
Greiner Bio-One starts international marketing of the cervical cancer triage test GynTect
Press ReleasesJena / Frickenhausen, January 20th, 2016 – With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the internationally active company had closed a marketing and distribution partnership with oncgnostics GmbH, who has developed and produces the GynTect® test, prior to Medica 2015. […]
oncgnostics and Greiner Bio-One Diagnostics sign Partnership Agreement
Press Releases